Scholarlink

Background <p>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a major global health issue, affecting nearly 30% of the population, especially in developed countries. A Delphi consensus in June 2023 redefined NAFLD as MASLD to better reflect its metabolic origins. MASLD is diagnosed by identifying hepatic steatosis through imaging or biopsy, along with at least one cardiometabolic risk factor. It is associated with liver-related complications such as fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), and extra hepatic conditions like cardiovascular and kidney disease, and metabolic syndrome. MicroRNAs (miR), which regulate gene expression and influence lipid metabolism, inflammation, and fibrosis, may serve as non-invasive biomarkers for MASLD. We aimed to assess the functional significance of circulating miR as accessible serum biomarkers for MASLD diagnosis.</p> Methods <p>In this case–control study, 30 MASLD patients and 20 healthy controls were evaluated. Diagnosis was based on clinical (anthropometric measures), biochemical, and imaging findings and severity was assessed using vibration-controlled transient elastography (VCTE). Serum levels of seven circulating MiRs were measured and correlated with metabolic and hepatic parameters.</p> Results <p>MASLD patients showed significantly elevated BMI, waist circumference, cholesterol, and triglycerides, and reduced HDL levels. miR-34a, miR-122, miR-21, miR-223, and miR-193a-5p were up regulated, while miR-422a and miR-29a were down regulated. miR-34a was the most predictive biomarker, followed by miR-223.</p> Conclusion <p>Specific circulating miR are closely linked to MASLD severity and may serve as effective non-invasive biomarkers for diagnosis, staging, and disease monitoring.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating microRNAs as potential non-invasive biomarkers for diagnosis and severity assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease: a case–control study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月1日

查看全文
  • Hanan M Nafeh,
  • Nourhan M Abbas,
  • Mohamed A El-Mokhtar,
  • Hebatallah M. Hassan,
  • Sahar M Hassany

摘要

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a major global health issue, affecting nearly 30% of the population, especially in developed countries. A Delphi consensus in June 2023 redefined NAFLD as MASLD to better reflect its metabolic origins. MASLD is diagnosed by identifying hepatic steatosis through imaging or biopsy, along with at least one cardiometabolic risk factor. It is associated with liver-related complications such as fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), and extra hepatic conditions like cardiovascular and kidney disease, and metabolic syndrome. MicroRNAs (miR), which regulate gene expression and influence lipid metabolism, inflammation, and fibrosis, may serve as non-invasive biomarkers for MASLD. We aimed to assess the functional significance of circulating miR as accessible serum biomarkers for MASLD diagnosis.

Methods

In this case–control study, 30 MASLD patients and 20 healthy controls were evaluated. Diagnosis was based on clinical (anthropometric measures), biochemical, and imaging findings and severity was assessed using vibration-controlled transient elastography (VCTE). Serum levels of seven circulating MiRs were measured and correlated with metabolic and hepatic parameters.

Results

MASLD patients showed significantly elevated BMI, waist circumference, cholesterol, and triglycerides, and reduced HDL levels. miR-34a, miR-122, miR-21, miR-223, and miR-193a-5p were up regulated, while miR-422a and miR-29a were down regulated. miR-34a was the most predictive biomarker, followed by miR-223.

Conclusion

Specific circulating miR are closely linked to MASLD severity and may serve as effective non-invasive biomarkers for diagnosis, staging, and disease monitoring.